Oncotarget

Research Papers:

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

Michael T. Barrett, _ Karen S. Anderson, Elizabeth Lenkiewicz, Mariacarla Andreozzi, Heather E. Cunliffe, Christine L. Klassen, Amylou C. Dueck, Ann E. McCullough, Srikanth K. Reddy, Ramesh K. Ramanathan, Donald W. Northfelt, Barbara A. Pockaj

Metrics: PDF 1105 views  |   HTML 434 views  |   ?  

here


Abstract

Michael T. Barrett1, Karen S. Anderson2, Elizabeth Lenkiewicz1, Mariacarla Andreozzi1, Heather E. Cunliffe3, Christine L. Klassen4, Amylou C. Dueck5, Ann E. McCullough6, Srikanth K. Reddy7, Ramesh K. Ramanathan8, Donald W. Northfelt8, Barbara A. Pockaj4

1Department of Research, Mayo Clinic in Arizona, Scottsdale, Arizona, United States of America

2Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America

3Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

4Division of General Surgery, Section of Surgical Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, United States of America

5Section of Biostatistics, Mayo Clinic in Arizona, Scottsdale, Arizona, United States of America

6Department of Pathology and Laboratory Medicine, Mayo Clinic in Arizona, Scottsdale, Arizona, United States of America

7Vanderbilt University, Nashville, Tennessee, United States of America

8Division of Hematology-Oncology, Mayo Clinic in Arizona, Scottsdale, Arizona, United States of America

Correspondence to:

Michael T. Barrett, e-mail: Barrett.michael@mayo.edu

Keywords: 9p24.1 amplicon, flow sorting, triple negative breast cancer, JAK2, PD-L1

Received: May 05, 2015     Accepted: June 22, 2015     Published: July 03, 2015

ABSTRACT

We used DNA content flow cytometry followed by oligonucleotide array based comparative genomic hybridization to survey the genomes of 326 tumors, including 41 untreated surgically resected triple negative breast cancers (TNBC). A high level (log2ratio ≥1) 9p24 amplicon was found in TNBC (12/41), glioblastomas (2/44), and colon carcinomas (2/68). The shortest region of overlap for the amplicon targets 9p24.1 and includes the loci for PD-L1, PD-L2, and JAK2 (PDJ amplicon). In contrast this amplicon was absent in ER+ (0/8) and HER2+ (0/15) breast tumors, and in pancreatic ductal adenocarcinomas (0/150). The PDJ amplicon in TNBCs was correlated with clinical outcomes in group comparisons by two-sample t-tests for continuous variables and chi-squared tests for categorical variables. TNBC patients with the PDJ amplicon had a worse outcome with worse disease-free and overall survival. Quantitative RT-PCR confirmed that the PDJ amplicon in TNBC is associated with elevated expression of JAK2 and of the PD-1 ligands. These initial findings demonstrate that the PDJ amplicon is enriched in TNBC, targets signaling pathways that activate the PD-1 mediated immune checkpoint, and identifies patients with a poor prognosis.

Author Information

Michael T. Barrett
Primary Contact  _

Karen S. Anderson

Elizabeth Lenkiewicz

Mariacarla Andreozzi

Heather E. Cunliffe

Christine L. Klassen

Amylou C. Dueck

Ann E. McCullough

Srikanth K. Reddy

Ramesh K. Ramanathan

Donald W. Northfelt

Barbara A. Pockaj


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4494